Repella Robert 4
4 · Vanda Pharmaceuticals Inc. · Filed Dec 11, 2012
Insider Transaction Report
Form 4
Repella Robert
SVP & Chief Commercial Officer
Transactions
- Award
Restricted Stock Unit
2012-12-07+18,750→ 18,750 total→ Common Stock (18,750 underlying) - Award
Employee Stock Option (Right to Buy)
2012-12-07+56,250→ 56,250 totalExercise: $3.12Exp: 2022-12-06→ Common Stock (56,250 underlying)
Footnotes (4)
- [F1]50% of the shares subject to this option shall vest in 48 equal monthly installments beginning January 7, 2013 (the "Initial Vesting Date"), provided Reporting Person remains continuously employed by the Issuer through the Initial Vesting Date. 50% of the shares subject to this option shall vest upon acceptance by the U.S. Food and Drug Administration of the Issuer's New Drug Application Filing for tasimelteon for the treatment of Non-24-Hour Disorder (the "Vesting Event"), provided Reporting Person remains continuously employed by the Issuer through the Vesting Event.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock.
- [F3]50% of the RSUs shall vest in four equal annual installments beginning January 1, 2014. 50% of the RSUs shall vest upon the Vesting Event, provided Reporting Person remains continuously employed by the Issuer through the Vesting Event. Vested shares will be delivered on the First Permissable Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F4]Not Applicable.